Bölümler
-
Toni Choueiri discusses this combination cohort of HIF inhibition plus VEGF-R inhibition.
-
Matt Galsky discusses the ASCO 2025 data regarding ctDNA from the NIAGARA neoadjuvant chemo +/- durvalumab study.
-
Eksik bölüm mü var?
-
Jeannie Hoffman-Censits discusses her randomized phase 2 adding SG to maintenence avelumab in mUC.
-
Monty Pal discusses more correlates from this trial including matched baseline and progression tissue samples.
-
David McDermott joins us on the heels of his outstanding discussion of the clinical science symposium on RCC biomarkers.
-
Practice Changing? 独断と偏見で選んだ注目演題について結果の予想も含めて議論しました。
-
Silke, Tom and Brian discuss what they are looking forward to at ASCO 2025
-
日本と海外の違いはあるのか？mHSPCとmCRPCのUromigos Scoreについて激論！！
-
Silke and Chris joins us to discuss our latest 'Uromigos Score' in which experts score the value of treatments for advanced prostate cancer. Several interesting themes emerge.
-
Mark Tyson from Mayo Clinic joins the podcast to discuss this replicating adenovirus and a high CR rate in BCG-unresponsive NMIBC
-
Viktor Grunwald joins to discuss the new data session from EIKCS
-
Neal Shore joins the show to discuss these exciting data from the American Urological Association Annual Meeting
-
今月Eur Urol OncolにPublishされたヨーロッパのエキスパートによるmRCCのコンセンサスについて日本との違いについて深い議論をしました！！
-
Part 2 of our series dives deeper into the explosion of ADC clinical drug development in China
-
Drs. Dingwei Ye and Yao Zhu from China join the show to talk about drug development in China amid the recent surge of GU clinical trials.
-
Drs. Alicia Morgans and Chuck Ryan join the show to talk about their new podcast.
- Daha fazla göster
